Core Viewpoint - The Hong Kong Stock Connect Non-Bank ETF (513750) experienced a decline of 2.21% on January 30, with a trading volume of 2.365 billion yuan, indicating market volatility and investor sentiment [1] Group 1: Fund Performance - The fund's share increased by 263 million shares, bringing the total shares to 20.979 billion, with a notable increase of 5.201 billion shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 39.136 billion yuan [1] - Since its inception on November 10, 2023, the fund has achieved a return of 86.51%, with a one-month return of 8.24% [1] Group 2: Management and Benchmark - The fund is managed by GF Fund Management Co., Ltd., with fund managers Luo Guoqing and Cao Shiyu overseeing its operations [1] - The performance benchmark for the fund is the return rate of the CSI Hong Kong Stock Connect Non-Bank Financial Theme Index, adjusted using valuation exchange rates [1]

Core Insights - The biotechnology industry is rapidly developing and is a key direction for global technological revolution and industrial upgrading, with innovative drugs being a core engine aligned with the "Healthy China" strategy [1] - By 2026, the Hong Kong stock market's biotechnology sector is expected to see a significant increase in merger and acquisition activities, with Goldman Sachs predicting record-high global pharmaceutical and biotechnology M&A volumes [1] - The Chinese biotechnology sector is currently driven by a combination of policy benefits, capital support, and technological breakthroughs, with a shift in regulatory focus from cost control to encouraging quality innovation [1][2] Industry Trends - There is a persistent demand for the diagnosis and treatment of diseases such as cancer and cardiovascular conditions, supported by increased consumer payment capacity and rising healthcare expenditures, providing substantial growth opportunities for the industry [2] - The industry is transitioning from "broad innovation" to "differentiated innovation and international development," with a significant number of innovative drugs expected to be approved in China by 2025 [2] - In 2025, 76 innovative drugs are projected to be approved in China, with over 80% being domestic innovations, and a record total of over $130 billion in licensing transactions for innovative drugs [2] Investment Opportunities - The Hang Seng Biotechnology Index (HSBIO.HI) highlights the investment value of high-purity and scarce biotechnology companies, focusing on leading firms in the sector with a low overlap with traditional pharmaceuticals [3] - The index includes 30 leading biotechnology companies listed in Hong Kong, with a significant portion of its weight concentrated in the top ten stocks, including WuXi Biologics and BeiGene [3] - The Guangfa Hang Seng Biotechnology ETF, launched to facilitate efficient investment in core biotechnology assets, offers T+0 trading and low fees, positioning it as an attractive option for investors looking to capitalize on the sector's growth [3][4]

Group 1 - The cross-border ETF market has seen significant inflows, with over 13.8 billion yuan in net purchases since the beginning of the year, bringing the total market size to nearly 978.8 billion yuan, approaching the 1 trillion yuan mark [1] - There are currently 25 cross-border ETF products with a scale exceeding 10 billion yuan, with the Hong Kong Stock Connect Technology ETF (159262) recently reaching a scale of 10.117 billion yuan, making it a new addition to the billion-yuan category [1] - GF Fund has a leading position in the cross-border ETF market, managing 11 cross-border ETFs, of which 5 have surpassed 10 billion yuan in scale, accounting for 45% of the total number of billion-yuan cross-border ETFs in the market [1][2] Group 2 - GF Fund's five billion-yuan products cover core assets and high-growth sectors across different markets, including the Nasdaq ETF (159941), which has a scale exceeding 30 billion yuan and an annualized return of over 17% since inception [2] - The Hong Kong Stock Connect Non-Bank Financial ETF (513750) is the only tool tracking the Hong Kong Stock Connect non-bank financial theme index, with over 68% exposure to the insurance industry [2] - The Hong Kong Stock Connect Innovative Drug ETF (513120) is the largest in its category, having increased by over 66% since 2025, while the Hong Kong Stock Connect Technology ETF (159262) and the Hang Seng Technology ETF (513380) focus on AI technology leaders and classic technology assets, respectively [2] Group 3 - GF Fund has been systematically developing its index business since 2008, establishing a comprehensive product line across A-shares, Hong Kong stocks, US stocks, and commodities, making it one of the most complete providers of index products [3] - The company's index investment management capabilities have been recognized by authoritative institutions, earning a five-star rating in the index fund management capability from the Ji'an Jinxin Fund Evaluation Center [3]

来源：新浪基金∞工作室 港股通非银ETF（513750）业绩比较基准为同期中证港股通非银行金融主题指数收益率(使用估值汇率 折算)，管理人为广发基金管理有限公司，基金经理为罗国庆、曹世宇，成立（2023-11-10）以来回报为 86.37%，近一个月回报为10.39%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月7日，港股通非银ETF（513750）跌0.11%，成交额34.66亿元。当日份额增加6.18亿份，最新份额为 172.30亿份，近20个交易日份额增加22.76亿份。最新资产净值计算值为321.18亿元。 ...

Group 1 - The article discusses the recent performance of the A-share market, highlighting a significant increase in the Shanghai Composite Index, which reached 4023 points, just 10 points shy of its previous high of 4034 points from November last year [11][13] - The overall market saw a trading volume of 2.5 trillion, indicating strong investor interest and participation [11] - Four main market hotspots were identified: the technology sector driven by semiconductor stocks, the success of Moutai's direct sales strategy, and a notable rise in insurance stocks [12][22][27] Group 2 - The technology sector, particularly semiconductor stocks, experienced a surge, with the sector rising over 4%, influenced by positive developments in overseas markets [17][19] - Moutai's direct sales strategy has shown initial success, leading to a 3.54% increase in its stock price, marking one of the largest single-day gains in the past year [22] - Insurance stocks also performed exceptionally well, with significant gains across the board, including a nearly 9% rise in New China Life Insurance [27][29]

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 来源：新浪基金∞工作室 港股通非银ETF（513750）业绩比较基准为同期中证港股通非银行金融主题指数收益率(使用估值汇率 折算)，管理人为广发基金管理有限公司，基金经理为罗国庆、曹世宇，成立（2023-11-10）以来回报为 73.50%，近一个月回报为4.78%。 12月29日，港股通非银ETF（513750）跌1.42%，成交额18.20亿元。当日份额增加4.42亿份，最新份额 为157.54亿份，近20个交易日份额增加7.63亿份。最新资产净值计算值为273.38亿元。 ...

Core Viewpoint - The Hong Kong insurance sector is experiencing significant gains, with major companies like China Ping An and China Taiping rising over 5% following a report from Morgan Stanley that includes China Ping An in its focus list and raises its target price [1] Group 1: Market Performance - As of 14:35, the non-bank financial theme index (931024) in Hong Kong has increased by over 3% [1] - The Hong Kong non-bank ETF (513750) is the only product tracking the non-bank financial theme index, which consists of 68.8% insurance, 12.8% Hong Kong Stock Exchange, and 14% securities [1] - The non-bank ETF has seen a net inflow of over 23.5 billion yuan this year, bringing its total size to 24.5 billion yuan [1] Group 2: Investment Opportunities - The Zhaoran team from CITIC Securities suggests that in the context of potential interest rate cuts by the Federal Reserve, the liquidity in the Hong Kong market is expected to improve, making the non-bank sector attractive [1] - There is an anticipated improvement in the performance of listed insurance companies, with a focus on the "Davis Double Play" investment opportunity, which highlights long-term growth and valuation recovery in the insurance industry [1]

Group 1 - The core viewpoint of the news is that the Hong Kong insurance sector is experiencing significant gains, with major companies like China Ping An and China Taiping seeing increases of 6%, and China Life rising by 4% [1] - Morgan Stanley has included China Ping An in its key focus list for mainland China and Hong Kong, maintaining a "preferred" rating and significantly raising its target prices: from 70 yuan to 85 yuan (+21%) for A-shares, and from 70 HKD to 89 HKD (+27%) for H-shares [1] - Morgan Stanley believes that China Ping An can capitalize on key growth opportunities in wealth management, healthcare, and elderly care, while market concerns are gradually being alleviated, paving the way for an increase in the company's valuation [1] Group 2 - Citic Securities' Zhao Ran team suggests that in the context of potential interest rate cuts by the Federal Reserve, the Hong Kong market is experiencing liquidity easing, which could benefit the non-bank sector [2] - The team highlights that the performance of listed insurance companies on both the asset and liability sides is expected to improve, recommending attention to the "Davis Double Play" investment opportunity, which focuses on long-term growth and valuation recovery in the insurance industry [2] Group 3 - The Hong Kong Stock Connect Non-Bank Financial Theme Index (931024) saw an intraday increase of over 3%, with the index being heavily weighted towards insurance, comprising 68.8% insurance, 12.8% Hong Kong Stock Exchange, and 14% securities [1] - The Hong Kong Stock Connect Non-Bank ETF (513750) is the only product tracking this index and has attracted significant capital inflows, with a net purchase exceeding 23.5 billion yuan this year, bringing its latest scale to 24.5 billion yuan [1]

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通非银ETF（513750）业绩比较基准为同期中证港股通非银行金融主题指数收益率(使用估值汇率 折算)，管理人为广发基金管理有限公司，基金经理为罗国庆、曹世宇，成立（2023-11-10）以来回报为 62.93%，近一个月回报为-3.13%。 来源：新浪基金∞工作室 12月3日，港股通非银ETF（513750）跌2.05%，成交额7.34亿元。当日份额减少1400.00万份，最新份额 为149.65亿份，近20个交易日份额增加12.30亿份。最新资产净值计算值为243.88亿元。 ...

Core Insights - The Hong Kong Stock Connect Non-Bank ETF (513750) increased by 0.24% on November 20, with a trading volume of 1.106 billion yuan [1] - The fund's shares rose by 93.5 million, bringing the total shares to 15.218 billion, with an increase of 2.494 billion shares over the past 20 trading days [1] - The latest net asset value is calculated at 25.696 billion yuan [1] - The fund's performance benchmark is the return rate of the CSI Hong Kong Stock Connect Non-Bank Financial Theme Index, using valuation exchange rates [1] - Managed by GF Fund Management Co., Ltd., the fund has achieved a return of 68.82% since its establishment on November 10, 2023, and a return of 2.56% over the past month [1]